Professor of Translational Research in Dentistry, Unit of Oral and Maxillofacial Medicine, Surgery and Pathology, School of Clinical Dentistry, University of Sheffield, Sheffield, UK.
Professor of Cardiology, Guy´s and St Thomas´ Hospital, London and Chair of Cardiology, Cleveland Clinic, London, UK.
Br Dent J. 2024 May;236(9):702-708. doi: 10.1038/s41415-024-7344-5. Epub 2024 May 10.
In 2008, National Institute for Health and Care Excellence (NICE) guidelines recommended against the use of antibiotic prophylaxis (AP) before invasive dental procedures (IDPs) to prevent infective endocarditis (IE). They did so because of lack of AP efficacy evidence and adverse reaction concerns. Consequently, NICE concluded AP was not cost-effective and should not be recommended. In 2015, NICE reviewed its guidance and continued to recommend against AP. However, it subsequently changed its wording to 'antibiotic prophylaxis against infective endocarditis is not routinely recommended'. The lack of explanation of what constituted routinely (and not routinely), or how to manage non-routine patients, caused enormous confusion and NICE remained out of step with all major international guideline committees who continued to recommend AP for those at high risk.Since the 2015 guideline review, new data have confirmed an association between IDPs and subsequent IE and demonstrated AP efficacy in reducing IE risk following IDPs in high-risk patients. New evidence also shows that in high-risk patients, the IE risk following IDPs substantially exceeds any adverse reaction risk, and that AP is therefore highly cost-effective. Given the new evidence, a NICE guideline review would seem appropriate so that UK high-risk patients can receive the same protection afforded high-risk patients in the rest of the world.
2008 年,英国国家卫生与临床优化研究所(NICE)指南建议不要在侵入性牙科操作(IDP)前使用抗生素预防(AP)来预防感染性心内膜炎(IE)。这是因为缺乏 AP 疗效证据和不良反应担忧。因此,NICE 认为 AP 不具有成本效益,不应推荐使用。2015 年,NICE 审查了其指南,并继续建议反对 AP。然而,它随后改变了措辞,改为“预防感染性心内膜炎的抗生素预防措施不常规推荐”。缺乏关于什么是常规(和非常规)的解释,或者如何管理非常规患者,导致了极大的混乱,NICE 仍然与所有主要的国际指南委员会不一致,这些委员会继续建议高危患者使用 AP。自 2015 年指南审查以来,新的数据证实了 IDP 与随后的 IE 之间存在关联,并证明了 AP 在降低高危患者 IDP 后 IE 风险方面的疗效。新的证据还表明,在高危患者中,IDP 后 IE 的风险大大超过任何不良反应风险,因此 AP 具有很高的成本效益。鉴于新的证据,NICE 指南的审查似乎是合适的,以便英国的高危患者能够获得与世界其他地区高危患者相同的保护。